FDA-cleared profile
Angiowave Imaging, Inc.
AngioWaveNet aids qualified physicians in analyzing and interpreting X-ray coronary angiographic cine images in adults by enhancing visibility of blood vessels, vascular structures, and related anatomy as a complement to standard angiographic cines.
Clinical fit
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Implementation
Use these fields to structure a vendor demo, security review, and implementation estimate.
This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K244002 before acceptance.
exact submission · checked 2026-09-04Later product-family features are not evidence that this cleared release includes them.
The FDA material describes an on-site Windows client and cloud processing location; current hosting responsibility, contracts, availability, security controls, and site configuration remain unverified.
exact submission · checked 2026-09-04FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA material describes a DICOM node, supported XA input, anonymization, communication, storage/retrieval, archiving, and a Windows 10/11 on-site client with cloud processing for processor-intensive tasks.
exact submission · checked 2026-09-04Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Adult coronary angiographic cines only; the output complements standard angiographic review and is not a standalone diagnosis or treatment decision; the FDA reader evidence is tied to version 1.0.0, the described acquisition systems, and the stated reader cohort.
exact submission · checked 2026-09-04Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K244002 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.
exact submission · checked 2026-09-04Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Angiography processing success in 31-patient reader-study cohort.
Tested version: AngioWaveNet version 1.0.0 configuration described in K244002Tasks reporting improved ease of visualization in 3,211 tasks across 97 angiograms/cines and 169 vessels.
Tested version: AngioWaveNet version 1.0.0 configuration described in K244002Reader-rated clinical decision impact in 31-patient reader-study cohort reviewed by three interventional cardiologists.
Tested version: AngioWaveNet version 1.0.0 configuration described in K244002Reader-study image set in 31-patient reader-study cohort.
Tested version: AngioWaveNet version 1.0.0 configuration described in K244002FDA 510(k) reader study and software verification for the exact AngioWaveNet version 1.0.0 configuration. · 31 patients selected from 50 sequential coronary angiography cases, reviewed by three experienced interventional cardiologists in July-August 2025.
exact submission · Tested version: AngioWaveNet version 1.0.0 configuration described in K244002 · n=31 · Sponsor or vendor studyK244002
The FDA material reports 97 angiograms/cines, 169 vessels, and 3,211 tasks; reader findings are version- and workflow-specific.
Economics and lifecycle
These are common procurement questions; unknown values remain visible until a source supports them.
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesThis is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Exact-identifier review does not prove absence of all product-family safety signals.
Buyer worksheet
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The discovery snapshot contains no PubMed or ClinicalTrials.gov candidates for K244002; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Sources
Sources accessed through 2026-09-04.
Alternatives
Shimadzu Corporation
Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational,...
Philips Medical Systems Nederland B.V.
EchoNavigator R5.0 supports an interventionalist or surgeon during cardiovascular treatment by combining live X-ray and live echocardiographic information.
Canon Medical Systems Corporation
Alphenix and INFX-8000V/B,S V9.6 with aEvolve FOV Extension are digital radiography and fluoroscopy systems for diagnostic and interventional angiography, with labeled real-time...
Cara Medical, Ltd.
CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying...